



472

PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:	)	Confirmation No. 4535
Wenge ZHONG, <i>et al.</i>	)	Group Art No. 1625
Serial No.: 10/736,289	)	Examiner: Zina Northington Davis
Filed: December 12, 2003	)	Docket No: 006539.00001

For: PYRID-2-ONE DERIVATIVES AND METHODS OF USE

**RESPONSE TO RESTRICTION REQUIREMENT**

Commissioner of Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

This paper is submitted in response to the Office Action mailed May 23, 2005 which set a one (1) month shortened statutory period for response. In the event a fee needs to be paid to enter this response, please charge Deposit Account No. 19-0733 for any such fee.

The Office Action requires restriction between what are asserted to be two separate and distinct inventions:

Group I – Claims 1-34 to a compound and pharmaceutical composition according to formula I

Group II – Claim 35 to a method of inhibiting cell proliferation using the compound of formula I

Group II – Claim 36 to a method of treating cancer using the compound of formula I

Group II – Claim 37 to a method of inhibiting a serine/threonine kinase using the compound of formula I

Group II – Claim 38 to a method of treating a neurological disorder using the compound of formula I

Group II – Claim 39 to a method of treating apoptosis using the compound of formula I


In response to the Restriction Requirement, applicants elect the invention of Group I (compounds and compositions), claims 1-34.

As noted in the office action, since the method claims are dependent on the compound claims, rejoinder is available in accordance with the provisions of MPEP 821.04.

Applicants request consideration of the pending claims.

Respectfully submitted,

Dated: 6-20-2005

By:   
Joseph M. Skerpon  
Registration No. 29,864

BANNER & WITCOFF, LTD.  
1001 G Street, N.W. - Eleventh Floor  
Washington, D.C. 20001-4597  
(202) 824-3000

JMS/bao

899626-1